natgillin/translations-raw huggingface dataset:
It is not known whether Rapiscan can pass into breast milk and will only be given to you if your doctor thinks it is necessary.
Ni znano, ali zdravilo Rapiscan prehaja v materino mleko, zato ga boste prejeli le, če zdravnik oceni, da je to potrebno.
The healthcare professionals will be responsible for the storage and disposal of this medicinal product.
Za shranjevanje in odstranjevanje tega zdravila je odgovorno zdravstveno osebje.
This belongs to a group of medicines called ‘coronary vasodilators'.
Slednja sodi v skupino zdravil, imenovanih "koronarni vazodilatatorji".
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000).
Pogostnosti so opredeljene kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in redki (≥ 1/10.000 do < 1/1.000).
• if you have low blood pressure (hypotension).
• če imate nizek krvni tlak (hipotenzijo),
Safety and tolerability of repeated use of this product within 24 hours has not been characterised.
Varnost in prenašanje pri ponavljajoči se uporabi zdravila v roku 24 ur nista bili opisani.
Rapiscan with food and drink
Zdravilo Rapiscan skupaj s hrano in pijačo
The risk of significant increases in blood pressure may be higher in patients with uncontrolled hypertension.
Tveganje pomembnega povišanja krvnega tlaka je lahko večje pri bolnikih z nenadzorovano hipertenzijo.
It may cause other symptoms (headache or shortness of breath) that could affect your ability to drive or use machinery.
Povzroči lahko tudi druge simptome (glavobol ali kratko sapo), ki lahko vplivajo na vašo sposobnost vožnje ali upravljanja s stroji.
All 1404 patients initially had a baseline MPI scan at rest in accordance with ASNC 2009 guidelines.
Vsem 1404 bolnikom so na začetku izvedli izhodiščno MPI slikanje v mirovanju v skladu s smernicami ASNC 2009.
Respiratory effects
Respiratorni učinki
Measurement of FFR
Merjenje FFR
• anxiety, difficulty sleeping
• anksioznost, težave s spanjem
Comparison of the images obtained with regadenoson to those obtained with adenosine was performed as follows.
Primerjava posnetkov, pridobljenih z uporabo regadenozona, s tistimi, pri katerih je bil uporabljen adenozin, je bila opravljena na naslednji način.
An intermediate phase follows, with a half-life on average of 30 minutes coinciding with loss of the pharmacodynamic effect.
Sledi vmesna faza s povprečno razpolovno dobo 30 minut, ki sovpada s pojenjanjem farmakodinamičnega učinka.
The use of bronchodilator therapy for symptoms was not different between regadenoson and placebo.
Uporaba zdravljenja simptomov z bronhodilatatorjem se ni razlikovala med regadenozonom in placebom.
The regadenoson plasma concentration-time profile in healthy volunteers is multi-exponential in nature and best characterised by 3-compartment model.
Profil plazemske koncentracije regadenozona v odvisnosti od časa pri zdravih prostovoljcih je multi-eksponencialen po svoji naravi in ga najbolje označuje 3-razdelčni model.
Heart rate returns to baseline within 10 minutes.
Srčni utrip se vrne na izhodiščnega v 10 minutah.
Subsequentially, patients from both groups, returned 1-14 days later, to undergo a second stress MPI regadenoson study without exercise.
V nadaljevanju so se bolniki iz obeh skupin vrnili 1-14 dni kasneje, da bi opravili drugo stresno študijo MPI z regadenozonom brez telesne vadbe.
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours.
Končno fazo sestavlja upad koncentracij v plazmi s približno 2-urno razpolovno dobo.
The safety and efficacy of regadenoson in children below the age of 18 years have not yet been established.
Varnost in učinkovitost regadenozona pri otrocih, starih do 18 let, še nista bili dokazani.
Repeat dosing within 10 minutes - except in patients where the duration of hyperaemia lasted for more than 10 minutes - caused a similar effect on peak and duration of maximum hyperaemia.
Ponovna uporaba v 10 minutah - razen pri bolnikih, pri katerih je hiperemija trajala več kot 10 minut - je, kar zadeva največjo izraženost in trajanje najizrazitejše hiperemije, privedla do podobnega učinka.
The disposition of regadenoson was studied in 18 subjects with various degrees of renal function and in 6 healthy subjects.
Razporeditev regadenozona so preučili pri 18 osebah z različnimi stopnjami okvare ledvic in pri 6 zdravih osebah.
• if you have high blood pressure that is not controlled, especially if this has been accompanied by recent episodes of nose bleed, headache or blurred or double vision.
• če imate visok krvni tlak, ki ni pod nadzorom, zlasti v povezavi z nedavnimi epizodami krvavitev iz nosu, glavobolov ali zamegljenega ali dvojnega vida,
Classification agreement Cohen's kappa
Klasifikacijsko ujemanje Cohenov kappa koeficient
Pregnancy and breast-feeding Before you are given Rapiscan, tell your doctor:
Nosečnost in dojenje Preden prejmete zdravilo Rapiscan, povejte svojemu zdravniku:
Particular care should be taken with the following medicines:
Pri uporabi naslednjih zdravil je potrebna posebna previdnost:
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
To navodilo za uporabo je na voljo v vseh uradnih jezikih EU/EGP na spletni strani Evropske agencije za zdravila
However, the maximum observed plasma concentrations as well as volumes of distribution estimates were similar across the groups.
Vendar pa so bili največje opažene koncentracije v plazmi in ocenjeni volumni porazdelitve v vseh skupinah podobni.
• discomfort in the bones and muscles
• nelagodje v kosteh in mišicah
Patients who did not achieve ≥ 85% maximum predicted heart rate (MPHR) and/or ≥ 5 METS (metabolic equivalents), transitioned into a 3-5 minutes walking recovery where during the first 3 minutes of recovery, patients were randomized 1:1.
Bolniki, ki niso dosegli ≥ 85 % največjega predvidenega utripa srca (MPHR-maximum predicted heart rate) in/ali ≥ 5 MET (presnovnih ekvivalentov), so prešli v 3-5 minutno okrevanje s hojo, kjer so bolnike v prvih 3 minutah okrevanja randomizirali v razmerju 1:1.
• if you have any heart or blood vessel condition, particularly one that gets worse when your blood pressure decreases.
• ali imate bolezni srca ali žil, zlasti take, ki se ob zmanjšanju krvnega tlaka poslabšajo.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije
The pharmacokinetic parameters of regadenoson have not yet been studied in the paediatric population (< 18 years).
Pediatrična populacija Farmakokinetičnih parametrov regadenozona do sedaj niso preučili pri pediatrični populaciji (< 18 let).
Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than half of the maximal effect within 10 minutes (see section 5.2).
Povprečna hitrost vrha se je povzpela na več kot dvakratno izhodiščno vrednost v 30 sekundah in se je zmanjšala za manj kot polovico največjega učinka v 10 minutah (glejte poglavje 5.2).
For further information, please refer to the complete Summary of Product Characteristics.
Za nadaljnje informacije glejte celoten Povzetek glavnih značilnosti zdravila.
Regadenoson causes a rapid increase in heart rate (see sections 4.4 and 5.1).
Regadenozon povzroči hitro zvišanje srčnega utripa (glejte poglavji 4.4 in 5.1).
The images from MPI 1 and MPI 2 were compared for presence or absence of perfusion defects.
Slike iz MPI 1 in MPI 2 so primerjali glede prisotnosti ali odsotnosti napak v perfuziji.
Age, gender, and race have minimal effects on the pharmacokinetics of regadenoson.
Starost, spol in rasa imajo minimalne učinke na farmakokinetiko regadenozona.
The incidence of a FEV1 reduction > 15% from baseline after regadenoson administration was assessed in three randomised, controlled clinical studies.
Incidenca zmanjšanja FEV1 > 15% od izhodišča po dajanju regadenozona je bila ocenjena v treh randomiziranih, nadziranih kliničnih študijah.
Consideration should be given to delaying regadenoson administration until blood pressure is well controlled
Treba je razmisliti o odložitvi uporabe regadenozona, dokler krvni tlak ni dobro nadzorovan.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Preden dobite zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
A total of 1,871 of these patients had images considered valid for the primary efficacy evaluation, including 1,294 (69%) men and 577 (31%) women with a median age of 66 years (range 26-93 years of age).
Pri skupno 1.871 od teh bolnikov so bili posnetki ocenjeni kot veljavni za ocenitev primarne učinkovitosti, vključno s 1.294 (69%) moških in 577 (31%) žensk z mediano starostjo 66 let (razpon starosti 26-93 let).
Your doctor may then give you an injection of a medicine called aminophylline that reduces these effects.
Zdravnik vam lahko da injekcijo zdravila, ki se imenuje aminofilin, ki te učinke ublaži.
A relationship between increased severity of disease and the increased incidence of dyspnoea was apparent in patients with asthma, but not in patients with COPD.
Razmerje med povečano resnostjo bolezni in povečano incidenco dispneje je bilo opazno pri bolnikih z astmo, ne pa pri bolnikih s KOPB.
Assessment of adverse reactions for regadenoson is based on safety data from clinical studies and postmarketing experience.
Ocena neželenih učinkov regadenozona temelji na podatkih varnosti, pridobljenih v kliničnih študijah in iz izkušenj v obdobju trženja.
The same applies to the FFR measurement where the maximal myocardial blood flow is decreased in presence of severe coronary artery stenosis.
Enako velja za meritev FFR, kjer je maksimalni krvni pretok v miokardu zmanjšan, kadar je prisotna huda stenoza koronarnih arterij.
Headache was reported by 27% of subjects who received regadenoson in clinical trials.
O glavobolu so poročali pri 27% osebah, ki so v kliničnih preskušanjih prejele regadenozon.
If your doctor thinks that you are having severe side effects, or the effects of Rapiscan are lasting too long, they may give you an injection of a medicine called aminophylline that reduces these effects.
Če vaš zdravnik meni, da imate hude neželene učinke ali če učinki zdravila Rapiscan trajajo predolgo, boste morda prejeli injekcijo zdravila, ki se imenuje aminofilin, ki te učinke ublaži.
Rapiscan is injected by a healthcare professional (a doctor, nurse or medical technician) in a medical facility where your heart and blood pressure can be monitored.
Zdravilo Rapiscan vam injicira zdravstveno osebje (zdravnik, medicinska sestra ali medicinski tehnik) v zdravstveni ustanovi, kjer lahko nadzirajo vaše srce in krvni tlak.
What Rapiscan is and what it is used for
Kaj je zdravilo Rapiscan in za kaj ga uporabljamo
The excretion of regadenoson in milk has not been studied in animals.
Izločanja regadenozona v mleko pri živalih niso preučili.
All adverse reactions are presented in the table below and are listed by system organ class and frequency.
Vsi neželeni učinki, predstavljeni v spodnji tabeli, so razvrščeni po organskih sistemih in pogostnosti.
In the pooled study population, 68% of patients had 0-1 segments showing reversible defects on the initial scan, 24% had 2-4 segments, and 9% had ≥ 5 segments.
V združeni populaciji študije je imelo 68% bolnikov 0-1 segment, ki so kazali reverzibilne okvare na začetnem slikanju, 24% jih je imelo 2-4 segmente in 9% jih je imelo ≥ 5 segmentov.
Within the dose range of 0.003-0.02 mg/kg (or approximately 0.18-1.2 mg) in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose.
V razponu odmerka 0,003-0,02 mg/kg (ali približno 0,181,2 mg) pri zdravih osebah očistek, končna razpolovna doba ali volumen porazdelitve niso odvisni od odmerka.
• difficulty in breathing (bronchospasm)
• oteženo dihanje (bronhospazem)
(n = 1,871)
Kombinirani študiji (n = 1.871)
Dipyridamole increases blood adenosine levels and the response to regadenoson may be altered when blood adenosine levels are increased.
Dipiridamol zvišuje ravni adenozina v krvi in odziv na regadenozon se lahko spremeni z zvišanjem ravni adenozina v krvi.
Regadenoson does not significantly inhibit the transporters OAT1, OAT3, OCT1, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP, ENT 1 or ENT2 at 1 µM.
Regadenozon ne zavira pomembno prenašalcev OAT1, OAT3, OCT1, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP, ENT 1 ali ENT2 pri koncentraciji 1 µM.
The radiopharmaceutical may be injected directly into the same catheter as Rapiscan.
Radiofarmacevtski izdelek se lahko injicira neposredno v isti kateter kot zdravilo Rapiscan.
Greater than 55% of the regadenoson dose is excreted unchanged in the urine and factors that decrease clearance do not affect the plasma concentration in the early stages after dosing when clinically meaningful pharmacologic effects are observed.
Več kot 55% odmerka regadenozona se nespremenjenega izloči v urinu in dejavniki, ki vplivajo na zmanjšanje očistka, ne vplivajo na koncentracije v plazmi v zgodnjih fazah po odmerjanju, ko so opazili klinično pomembne farmakološke učinke.
Contents of the pack and further information
Vsebina pakiranja in dodatne informacije
Very common Electrocardiogram ST segment changes Common
Zelo pogosti spremembe segmentov ST v elektrokardiogramu
Animal studies on pre- and post-natal development have not been conducted.
Študij na živalih glede prenatalnega in postnatalnega razvoja niso izvedli.
• Second or third degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning artificial pacemaker.
• disfunkcija atrioventrikularnega (AV) bloka ali sinusnega vozla druge ali tretje stopnje, razen če imajo bolniki delujoč umetni spodbujevalnik,
Therefore, regadenoson would be expected to have no or negligible influence on the ability to drive or use machines once treatment has been completed and these reactions have resolved.
Zato se pričakuje, da regadenozon nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje ali upravljanja s stroji po zaključku zdravljenja ali izzvenetju teh učinkov.
If you have any further questions, ask your doctor or pharmacist.
• Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
Millmount Healthcare Limited, Block 7, City North Business Campus, Stamullen, Co Meath, K32 YD60 Ireland
Millmount Healthcare Limited, Block 7, City North Business Campus, Stamullen, Co Meath, K32 YD60, Irska
Your heart rate and blood pressure will be monitored.
Vaš srčni utrip in krvni tlak bodo nadzirali.
The baseline MPI scans at rest and those without exercise at 1-14 days later from both groups, constituted the MPI 2 phase.
Izhodiščna slikanja MPI v mirovanju in tista brez vadbe v času 1-14 dni kasneje iz obeh skupin predstavljajo fazo MPI 2.
• high blood pressure, paleness, cold extremities
• visok krvni tlak, bledica, hladne okončine
Adverse reactions in most patients receiving regadenoson in clinical trials were mild, transient (usually resolving within 30 minutes after receiving regadenoson) and required no medical intervention.
Neželeni učinki pri večini bolnikov, ki so prejeli regadenozon v kliničnih študijah, so bili blagi, prehodni (običajno so izzveneli v 30 minutah po prejemu regadenozona) in niso zahtevali medicinskega poseganja.
In the measurement of FFR, the time to peak maximum hyperaemia was 30±13 seconds.
Pri merjenju FFR je čas, po katerem je prišlo do najizrazitejše hiperemije, znašal 30 ± 13 sekund.
Also, there was no apparent effect of 200 mg or 400 mg of caffeine on regadenoson plasma concentrations.
Poleg tega ni bilo opaznih vplivov 200 mg ali 400 mg kofeina na plazemske koncentracije regadenozona.
In a study of healthy volunteers, symptoms of flushing, dizziness and increased heart rate were assessed as intolerable at regadenoson doses greater than 0.02 mg/kg.
V študiji z zdravimi prostovoljci so le ti simptome vročinskih valov, omotice in hitrejšega srčnega utripa ocenili kot nevzdržne pri odmerkih regadenozona, večjih od 0,02 mg/kg.
A decision should be made whether to discontinue breastfeeding or to abstain from regadenoson administration taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z regadenozonom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Repeated use
Ponavljajoča se uporaba
The mean duration of hyperaemic plateau was 163 (±169) seconds and maximum hyperaemia lasted at least 19 seconds in 90% of patients, however, in the individual patient the duration of hyperaemia varied between 10 seconds to more than 10 minutes.
Obdobje hiperemije je v povprečju trajalo 163 (± 169) sekund, najizrazitejša hiperemija je pri 90 % bolnikov trajala vsaj 19 sekund, vendar pa je pri posameznih bolnikih obdobje hiperemije trajalo od 10 sekund do več kot 10 minut.
This medicine contains less than 1 mmol sodium (23 mg) per dose.
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek.
LABELLING
A. OZNAČEVANJE
What you need to know before you are given Rapiscan
Kaj morate vedeti, preden boste prejeli zdravilo Rapiscan
Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of medicinal products metabolised by these cytochrome P450 enzymes.
Regadenozon ne zavira presnove substratov za CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP3A4 v mikrosomih človeških jeter, kar kaže, da ni verjetno, da bi vplival na farmakokinetiko zdravil, ki jih presnavljajo ti encimi citokroma P450.
The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection of regadenoson and parallels the onset of the pharmacodynamic response (see section 5.1).
Največja koncentracija regadenozona v plazmi se doseže v 1 do 4 minutah po injiciranju regadenozona in ustreza nastopu farmakodinamičnega odziva (glejte poglavje 5.1).
• low blood pressure which may result in fainting or mini strokes (including weakness of the face or an inability to speak).
• nizek krvni tlak, ki lahko povzroči omedlevico ali majhne kapi (vključno z oslabelostjo obraza ali nezmožnostjo govoriti).
These images show how well blood flows to the muscles of the heart.
Posnetek prikazuje, kako dobro kri priteka v srčne mišice.
A scan of your heart will be made after enough time has passed to allow the radiopharmaceutical to reach the heart muscle.
Vaše srce bodo slikali, ko mine dovolj časa, da radiofarmacevtski izdelek doseže srčno mišico.
For FFR measurement, a diagnosis of inducible ischemia was made according to the measurement of FFR of 0.8 (>0.8 represents the absence of inducible ischemia vs ≤ 0.8 representing the presence of inducible ischemia).
Pri meritvi FFR je bila diagnoza inducibilne ishemije določena glede na izmerjeno FFR v vrednosti 0,8 (> 0,8 predstavlja odsotnost inducibilne ishemije, ≤ 0,8 pa predstavlja prisotnost inducibilne ishemije).
In healthy volunteers, 57% of the regadenoson dose is excreted unchanged in the urine (range 19-77%), with an average plasma renal clearance around 450 ml/min, i.e., in excess of the glomerular filtration rate.
Pri zdravih prostovoljcih se je 57% odmerka regadenozona nespremenjenega izločilo v urinu (razpon 19-77%), s povprečnim ledvičnim očistkom v plazmi približno 450 ml/min, tj. več kot je stopnja glomerularne filtracije.
In postmarketing experience, syncope and transient ischaemic attacks have been reported.
V izkušnjah po začetku trženja so poročali o sinkopi in tranzitornih ishemičnih atakah.
• if you have a condition that causes fits (seizures), such as epilepsy, or if you have ever had fits.
• ali imate bolezen, ki povzroča napade, kot je epilepsija, ali če ste kdaj imeli napade,
Therefore, 1147 patients were randomized in two groups: 578 patients from the exercise with regadenoson group and 569 from the regadenoson only group to either 3 minutes recovery (for the exercise with regadenoson group) or at rest 1 hour later (for the regadenoson only group).
Zato so 1147 bolnikov randomizirali v dve skupini: 578 bolnikov v skupino vadbe z regadenozonom in 569 v skupino samo z regadenozonom, z uporabo regadenozona bodisi 3 minute po začetku okrevanja (za skupino vadbe z regadenozonom) ali v mirovanju 1 uro pozneje (za skupino samo regadenozon).
In a patient with a long QT syndrome, sympathetic stimulation can result in less shortening of the QT interval than is normal and may even cause a paradoxical increase in the QT interval.
Pri bolnikih s sindromom podaljšanega intervala QT lahko simpatična stimulacija povzroči manjše skrajšanje intervala QT kot je normalno in povzroči celo paradoksalno zvišanje intervala QT.
Up to three consecutive injections of regadenoson (100 and 200 μg) have been tested in healthy volunteers, and two consecutive doses of 400 μg in healthy volunteers, as well as in patients assessed for FFR.
Pri zdravih prostovoljcih so preizkušali do tri zaporedna injiciranja regadenozona (100 in 200 μg), dva zaporedna 400 μg odmerka pa so preizkušali pri zdravih prostovoljcih, pa tudi pri bolnikih, pri katerih so izvedli meritev FFR.
Regadenoson may cause clinically significant increases in blood pressure, which in some patients can lead to hypertensive crisis (see section 4.8).
Regadenozon lahko povzroči klinično pomembna zvišanja krvnega tlaka, ki lahko pri nekaterih bolnikih pripeljejo do hipertenzivne krize (glejte poglavje 4.8).
The ADVANCE MPI 1 and ADVANCE MPI 2 studies, individually and combined, demonstrated that regadenoson is similar to adenosine in assessing the extent of reversible perfusion abnormalities:
Študiji ADVANCE MPI 1 in ADVANCE MPI 2 sta posamično in kombinirano pokazali, da je regadenozon podobno adenozinu pri ocenjevanju obsega reverzibilnih perfuzijskih abnormalnosti:
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1,
Mean plasma concentrations increased in a dose-related manner and by successive doses as observed in healthy volunteers.
Povprečne koncentracije v plazmi so se povečevale sorazmerno z odmerkom in z zaporednimi odmerki, kot so opažali pri zdravih prostovoljcih.
The headache was considered severe in 3% of subjects.
Glavobol je bil pri 3% oseb hud.
• pain in the back, arms, legs, neck or jaw
• bolečina v hrbtu, rokah, nogah, vratu ali čeljusti
Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations, ATC code: C01EB21
Farmakoterapevtska skupina: zdravljenje srca, druga zdravila za bolezni srca, oznaka ATC: C01EB21
• if you have chest pain that occurs unpredictably (unstable angina) and that has not improved after treatment.
• če imate bolečino v prsih, ki je ni mogoče napovedati (nestabilno angino pektoris), in če se stanje po zdravljenju ni izboljšalo,
• the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated (see sections 4.2 and 5.1).
• meritvi funkcionalne pretočne rezerve (FFR - fractional flow reserve) stenoze edine koronarne arterije med invazivno koronarno angiografijo, kadar ne pričakujemo ponovnih meritev FFR (glejte poglavji 4.2 in 5.1).
Your doctor will only give you Rapiscan if it is clearly necessary.
Zdravnik vam bo dal zdravilo Rapiscan le, če je to nujno potrebno.
Rapiscan solution for injection is a clear, colourless solution with no particles visible.
Zdravilo Rapiscan raztopina za injiciranje je bistra, brezbarvna raztopina brez vidnih delcev.
Safety and tolerability testing
Preskušanje varnosti in prenašanja
Pack size of 1.
Velikost pakiranja 1.
The scan uses a radioactive substance called a ‘radiopharmaceutical' to create images.
Pri slikanju se uporablja radioaktivna snov, imenovana "radiofarmacevtski izdelek", ki omogoči nastanek posnetka.